Bayer Loses Yaz Patent in Federal Court of Appeals: Generic Yaz Versions Begin (Stealing) Marketshare
Bayer was recently dealt a setback in a Federal Court of Appeals in Washington. Their patent on Yaz, a contraceptive pill, was deemed to no longer be worthy of patent protection. Bayer’s patent on Yaz expires in June 2014. As a result of this ruling, Actavis Inc. and Novartis AG can sell generic versions of the birth control pill. Though the ruling now gives other pharmaceutical companies the ability to legally compete against Bayer in the drospirenone contraceptive pill market, generic and inexpensive versions of Yaz-like drugs are driving Continue Reading
FDA Releases New Pradaxa Warning about Pradaxa Stroke, Heart Attack, and Blood Clots
Submit Your Claim On December 19, the U.S. Food and Drug Administration (FDA) released a safety announcement regarding the anticoagulant medicine known as Pradaxa. Pradaxa, known generically as dabigatran etexilate mesylate, is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., a German pharmaceutical company. The intention behind the FDA Pradaxa safety announcement is to inform health care providers and the public about the new risks associated with Pradaxa ingestion. In the release, the FDA warns that Pradaxa “should not be used to prevent stroke or blood clots (major thromboembolic events) in Continue Reading
Stryker Recalls Rejuvenate and ABG II Modular Hip Replacement Systems
In July 2012, Stryker issued a press release with information about a voluntary recall of its Rejuvenate modular-neck stems and its ABG II modular-neck stems, both of which are hip replacement systems manufactured and marketed by Stryker. The medical device manufacturer made the decision to voluntarily recall the Rejuvenate and ABG II hip replacement systems due to reports of fretting and corrosion as well as severe inflammation of adjacent tissues. In the Stryker recall press release, Stuart Simpson, Stryker’s Vice President and General Manager, Hip Reconstruction, states that, “given Continue Reading
Antiepileptic Drug Topamax Causes Congenital Oral Defects
Published October 23, 2012 by LawsuitInformation.org Topamax (topiramate) is an antiepileptic and antiseizure drug used to treat seizures in patients suffering from epilepsy. Topamax is also used to treat people suffering from migraine headaches. This anticonvulsant medication is manufactured, distributed, and marketed by Ortho-McNeil-Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. Though Topamax has been approved by the U.S. Food and Drug Administration (FDA), the drug’s label has recently been updated to reflect the significant health risk the antiepileptic drug poses to proper fetal development. The FDA released Continue Reading
Discover Card & Capital One Pay Settlements for Telemarketing Fraud
Published October 16, 2012 by LawsuitInformation.org Late last month, a settlement was reached in a lawsuit between Discover Card and the Consumer Financial Protection Bureau and the FDIC. Discover Card had been charged by federal regulators and consumers of fraudulent business practices. In the federal regulators’ investigation, they discovered that the credit card company’s telemarketers would use ambiguous and vague language when introducing credit card customers to Discover Card’s various programs. Often, these telephone marketing strategies would employ the technique of speaking quickly so as to become unintelligible. Often, Continue Reading
New York Woman Granted Second Chance to Fight Debt Collector’s Fraudulent Tactics
Published September 11, 2012 on Carey & Danis In the lawsuit, Easterling v. Collecto, Inc., a judge ruled last month that the debt collection company based in Massachusetts known as Collecto , Inc., used deceptive trade practices in an effort to convince the plaintiff, Berlincia Easterling, that her student loans could not be dissolved when filing for bankruptcy. The debt collection company sent Easterling a letter with language stating that her student loan debt was nondischargeable, and thus, must still be paid to Collecto, Inc. A U.S. Court of Continue Reading
Bayer 2012 Profits Impacted by Yaz and Yasmin Lawsuits
Published August 23, 2012 on LawsuitInformation.org It has been reported that Bayer, the German pharmaceutical giant responsible for the development of Yaz and Yasmin, the health threatening birth control pills of ill repute, has created what is essentially a savings account in the amount of 500 million euros for the purpose of future Yaz and Yasmin lawsuits. In a study conducted by the U.S. Food and Drug Administration (FDA) of Yaz and Yasmin, the FDA uncovered the high risk of blood clot development and a number of other serious Continue Reading
Barclays Bank Account Protector Program Class Action
Carey Danis & Lowe is currently investigating claims that Barclays Bank is engaging in unfair and deceptive trade practices in connection with the sale and administration of their Account Protector program, which is a debt suspension / debt cancellation plan offered to its card members for a fee. In particular, CD&L is investigating claims that Barclays Bank enrolls card members into their payment protection plan without first determining whether the consumer is qualified to ever receive benefits under the program. The result is that card members are paying fees Continue Reading
Bank of America Credit Protection Plus Class Action
Carey Danis & Lowe is currently investigating claims that Bank of America is engaging in unfair and deceptive trade practices in connection with the sale and administration of their Credit Protection Plus program, which is a debt suspension / debt cancellation plan offered to its card members for a fee. In particular, CD&L is investigating claims that Bank of America enrolls card members into their payment protection plan without first determining whether the consumer is qualified to ever receive benefits under the program. The result is that card members Continue Reading
Banana Republic Card Security Program Class Action
Carey Danis & Lowe is currently investigating claims that Banana Republic is engaging in unfair and deceptive trade practices in connection with the sale and administration of their Card Security Program, which is a debt suspension / debt cancellation plan offered to its card members for a fee. In particular, CD&L is investigating claims that Banana Republic enrolls card members into their payment protection plan without first determining whether the consumer is qualified to ever receive benefits under the program. The result is that card members are paying fees even though Continue Reading
